Orchestra BioMed Holdings annual operating margin
2022
2023
2024
2025
Orchestra BioMed Holdings's operating margin was −154.73% for fiscal 2025.
View full Orchestra BioMed Holdings company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −154.73% | +2282.76 pp |
| 2024 | 2024-12-31 | −2,437.49% | −571.33 pp |
| 2023 | 2023-12-31 | −1,866.16% | −941.82 pp |
| 2022 | 2022-12-31 | −924.34% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −25,404.55% | −23092.70 pp |
| Q1 2026 | 2026-03-31 | −20,069.09% | −17889.25 pp |
| Q4 2025 | 2025-12-31 | 21.85% | +6613.55 pp |
| Q3 2025 | 2025-09-30 | −2,359.23% | −703.51 pp |
| Q2 2025 | 2025-06-30 | −2,311.84% | −144.88 pp |
| Q1 2025 | 2025-03-31 | −2,179.84% | +146.45 pp |
| Q4 2024 | 2024-12-31 | −6,591.70% | −1827.96 pp |
| Q3 2024 | 2024-09-30 | −1,655.72% | +1810.62 pp |
| Q2 2024 | 2024-06-30 | −2,166.97% | −751.01 pp |
| Q1 2024 | 2024-03-31 | −2,326.29% | −1334.45 pp |
| Q4 2023 | 2023-12-31 | −4,763.74% | −3872.72 pp |
| Q3 2023 | 2023-09-30 | −3,466.35% | −2600.74 pp |
| Q2 2023 | 2023-06-30 | −1,415.96% | +487.78 pp |
| Q1 2023 | 2023-03-31 | −991.84% | −399.69 pp |
| Q4 2022 | 2022-12-31 | −891.02% | — |
| Q3 2022 | 2022-09-30 | −865.61% | — |
| Q2 2022 | 2022-06-30 | −1,903.74% | — |
| Q1 2022 | 2022-03-31 | −592.15% | — |
Across the available reported history, Orchestra BioMed Holdings's operating margin increased from −2,437.49% to −154.73%, a change of +2282.76 percentage points. The latest reported quarter, Q2 2026, shows −25,404.55%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Orchestra BioMed Holdings filings at SEC.gov ↗